eloralintide vs retatrutide Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Mazdutide vs retatrutide: dual agonist

The earliest realistic UK approval is late 2027 to mid 2028, with NHS access likely from 2029 at the soonest

Some users report receiving medication within 2-3 days

- What kind of follow-up appointments or tests will be needed after starting a GLP-1

However, if you notice any of the following, reach out to your provider: A firm lump, swelling, or visible bulge under the skin that doesnt resolve within 12 weeks Persistent redness, warmth, or pain at the injection site Significant bruising that doesnt resolve An unexplained change in how well your medication seems to be working, such as appetite changes or inconsistent blood sugar control Any signs of an allergic reaction, such as hives, swelling beyond the injection site, or difficulty breathing

Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment